Compare GoPro Inc (GPRO) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? GoPro Inc trades at $1.1 (market cap $243.50M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 30.9× GoPro Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| GPRO | SYRE | |
|---|---|---|
Market Cap | $243.50M | $7.52B |
Volume | 7,074,005 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $2.31 | $108.92 |
52-Week Low | $0.58 | $22.18 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $302.28M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro trades at $1.16, down 2.52% today, as the stock consolidates after a volatile surge driven by merger news and influencer investment. The company faces fundamental challenges with negative profit margins and cash flow, though valuation ratios appear attractive with P/E of 4.56 and P/S of 0.34. Recent developments include a $285 million merger agreement with Starman Optical and YouTube creator Markiplier taking an 8.5% stake, driving significant price volatility.
The merger with Starman Optical offers strategic repositioning into AI data centers and defense markets, but shareholder lawsuits question the $1.14 per share valuation. While technical indicators show bullish momentum, fundamental weaknesses and competitive pressures from smartphones create significant investment risk. Analyst consensus remains cautious with only 21% buy ratings.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
